Green oat extract: attention and memory tasks
Results of cognitaven and Neuravena studies on attention and selected tasks.
Key points
- In healthy adults aged 35–65, cognitaven improved performance on selected moving-target tracking and block-sequence memory tasks compared with placebo on day 29. The result applies to specific tasks and product doses. [1] See the evidence 1 2
- The other cognitaven tasks showed no sustained advantage; in one attention test at the intermediate dose, accuracy was lower than placebo four hours after intake. Another extract, Neuravena, showed no advantage in attention tests over 12 weeks in healthy people over 60. [1] [2] See the evidence 1 2
Practical guide
Check the findings and their applicability to your situation.
Green oat extracts were studied in different laboratory tests.
Key points
Why these conclusions
Task results
At 430 or 1,290 mg cognitaven product daily — 300 or 900 mg extract itself — on day 29 participants tracked a target more accurately while counting and remembered a block sequence better than with placebo. Many tasks and time points were tested; certainty is low — 2 out of 4. [1] [3] [4] [5] [2]
The other tasks showed no sustained advantage; at 860 mg of product accuracy on one attention test four hours after intake on day 29 was lower than placebo. Similar worsening was not seen in other tests. [1]
Healthy people over 60 took 1,500 mg Neuravena daily for 12 weeks; tests were conducted at least 18 hours after the last dose. No advantage in attention and concentration was found, certainty is low — 2 out of 4. [2]
On day 29, participants tracked a moving target more accurately with a cursor while subtracting numbers aloud. Standardized difference from placebo d = 0.54 at 430 mg (p = 0.032) and d = 0.94 at 1,290 mg (p < 0.001). These values are not percentages of improvement.
| Parameter | Data |
|---|---|
| Result | On day 29, participants tracked a moving target more accurately with a cursor while subtracting numbers aloud. Standardized difference from placebo d = 0.54 at 430 mg (p = 0.032) and d = 0.94 at 1,290 mg (p < 0.001). These values are not percentages of improvement. |
| Participants | Healthy adults aged 35–65: 132 allocated to four groups, 126 included in the day-29 analysis |
| Form | cognitaven capsules — green oat extract with excipients |
| Dose | 430 or 1,290 mg of product daily — 300 or 900 mg of extract itself respectively; in the morning, three capsules in total including placebo capsules |
| Dose basis | 430 or 1,290 mg of product daily — 300 or 900 mg of extract itself respectively; in the morning, three capsules in total including placebo capsules |
| Comparison | Capsules with maltodextrin, identical in appearance |
| Duration | 29 days; tests on day 29 before the morning dose and 2 and 4 hours afterward |
| Certainty | 2/4: Final groups had 33 people on placebo, 33 on 430 mg, 32 on 860 mg and 28 on 1,290 mg. Many tasks and time points were tested. The result applies to the specific extract and laboratory tasks. It does not mean the same change in memory or attention in daily life. The manufacturer Anklam Extrakt funded the work; two authors were its employees. |
| Body of evidence | 1 publication |
| Sources | [1] |
On day 29, participants performed better on the Corsi block-sequence memory task. Standardized difference from placebo d = 0.64 at 430 mg (p = 0.017) and d = 0.61 at 1,290 mg (p = 0.020), averaged over the three measurements that day.
| Parameter | Data |
|---|---|
| Result | On day 29, participants performed better on the Corsi block-sequence memory task. Standardized difference from placebo d = 0.64 at 430 mg (p = 0.017) and d = 0.61 at 1,290 mg (p = 0.020), averaged over the three measurements that day. |
| Participants | Healthy adults aged 35–65: 132 allocated to four groups, 126 included in the day-29 analysis |
| Form | cognitaven capsules — green oat extract with excipients |
| Dose | 430 or 1,290 mg of product daily — 300 or 900 mg of extract itself respectively; in the morning, three capsules in total including placebo capsules |
| Dose basis | 430 or 1,290 mg of product daily — 300 or 900 mg of extract itself respectively; in the morning, three capsules in total including placebo capsules |
| Comparison | Capsules with maltodextrin, identical in appearance |
| Duration | 29 days; tests on day 29 before the morning dose and 2 and 4 hours afterward |
| Certainty | 2/4: Final groups had 33 people on placebo, 33 on 430 mg, 32 on 860 mg and 28 on 1,290 mg. Many tasks and time points were tested. The result applies to the specific extract and laboratory tasks. It does not mean the same change in memory or attention in daily life. The manufacturer Anklam Extrakt funded the work; two authors were its employees. |
| Body of evidence | 1 publication |
| Sources | [1] |
The other tasks showed no sustained advantage over placebo. At 860 mg, four hours after intake on day 29, accuracy on one attention test (RVIP) was lower, d = 0.62 (p < 0.001); similar worsening was not seen in other tests.
| Parameter | Data |
|---|---|
| Result | The other tasks showed no sustained advantage over placebo. At 860 mg, four hours after intake on day 29, accuracy on one attention test (RVIP) was lower, d = 0.62 (p < 0.001); similar worsening was not seen in other tests. |
| Participants | Healthy adults aged 35–65: 132 allocated to four groups, 126 included in the day-29 analysis |
| Form | cognitaven capsules — green oat extract with excipients |
| Dose | 430, 860 or 1,290 mg of product daily — 300, 600 or 900 mg of extract itself; in the morning, three capsules in total including placebo capsules |
| Dose basis | 430, 860 or 1,290 mg of product daily — 300, 600 or 900 mg of extract itself; in the morning, three capsules in total including placebo capsules |
| Comparison | Capsules with maltodextrin, identical in appearance |
| Duration | 29 days; tests on day 29 before the morning dose and 2 and 4 hours afterward |
| Certainty | 2/4: Final groups had 33 people on placebo, 33 on 430 mg, 32 on 860 mg and 28 on 1,290 mg. Many tasks and time points were tested. The result applies to the specific extract and laboratory tasks. It does not mean the same change in memory or attention in daily life. The manufacturer Anklam Extrakt funded the work; two authors were its employees. |
| Body of evidence | 1 publication |
| Sources | [1] |
No advantage was found in attention and concentration tests. In the main color-naming test, the mean number of uncorrected errors was 2.2 on extract and 2.1 on placebo (p = 0.72). The overall attention measure also did not differ (p = 1.00).
| Parameter | Data |
|---|---|
| Result | No advantage was found in attention and concentration tests. In the main color-naming test, the mean number of uncorrected errors was 2.2 on extract and 2.1 on placebo (p = 0.72). The overall attention measure also did not differ (p = 1.00). |
| Participants | 42 healthy people over 60 started the trial; 37 completed both periods, mean age 67 years |
| Form | Neuravena EFLA955 green oat extract capsules |
| Dose | 1,500 mg extract daily: five capsules with 300 mg extract each |
| Dose basis | 1,500 mg extract daily: five capsules with 300 mg extract each |
| Comparison | Placebo capsules with microcrystalline cellulose, lactose and colorants |
| Duration | 12 weeks each of extract and placebo; 24 weeks total. Testing at least 18 hours after the last dose |
| Certainty | 2/4: Small crossover trial: 37 people completed both periods. The article does not describe a separate break between them. It examined a sustained result at least 18 hours after the last dose, not the first hours after intake. Participants had normal memory and attention at baseline. The authors accounted for multiple comparisons when assessing many tests. Frutarom funded the work and supplied the capsules. |
| Body of evidence | 1 publication |
| Sources | [2] |
Information from the source
If allergic to oats, avoid oat foods and supplements. With celiac disease, choose oats labeled gluten-free: ordinary flakes may contain wheat, rye or barley. Even pure oats cause symptoms in a small proportion of people with celiac disease because of the protein avenin; discuss a suitable amount with a doctor or dietitian. In the CP105F tablet trial, gastrointestinal adverse events were reported in 23.4%, 34.8% and 66.7% of participants at 1.5, 3 and 6 g of beta-glucan daily respectively, and 36.9% on placebo. These are data for a specific product over 12 weeks. For green oat herb preparations, the EMA does not recommend use during pregnancy, breastfeeding or in children under 12 because of insufficient data. These restrictions concern herb preparations, not oats as ordinary food. Oat herb preparations may impair safe driving and operation of machinery: if affected, refrain from these activities. With celiac disease also check the extract’s composition; liquid preparations may contain alcohol. [6] [7] [4] [8]
Information from the source
Oat foods: grain, flakes and bran contain a mixture of dietary fibers. Beta-glucan is only part of this mixture. Cholesterol studies used 1.5–6 g of beta-glucan daily; a separate satiety experiment used 66.8 g of dry flakes in which 2.68 g of beta-glucan was measured. CP105F tablets: 1.5, 3 and 6 g of beta-glucan daily were studied. Over 12 weeks they did not reduce LDL compared with placebo. Green oat extracts: cognitaven contains 70% extract itself and 30% excipients. Thus 430, 860 and 1,290 mg of product correspond to 300, 600 and 900 mg of extract. Neuravena was studied separately at 1,500 mg of extract daily. These doses cannot be converted into servings of oatmeal. [3] [4] [5] [1] [2]
Sources
- Acute and Chronic Effects of Green Oat (Avena sativa) Extract on Cognitive Function and Mood during a Laboratory Stressor in Healthy Adults: A Randomised, Double-Blind, Placebo-Controlled Study in Healthy Humans. https://pubmed.ncbi.nlm.nih.gov/32485993/
- Chronic effects of a wild green oat extract supplementation on cognitive performance in older adults: a randomised, double-blind, placebo-controlled, crossover trial. https://pubmed.ncbi.nlm.nih.gov/22690320/
- Effects of Oat Beta-Glucan Intake on Lipid Profiles in Hypercholesterolemic Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. https://pubmed.ncbi.nlm.nih.gov/35631184/
- Supplementation with a β-glucan tablet has no effect on hyperlipidemia: a randomized, placebo-controlled clinical trial. https://pubmed.ncbi.nlm.nih.gov/37054888/
- Instant Oatmeal Increases Satiety and Reduces Energy Intake Compared to a Ready-to-Eat Oat-Based Breakfast Cereal: A Randomized Crossover Trial. https://pubmed.ncbi.nlm.nih.gov/26273900/
- Coeliac disease - Treatment. https://www.nhs.uk/conditions/coeliac-disease/treatment/
- Eating, Diet, & Nutrition for Celiac Disease - NIDDK. https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease/eating-diet-nutrition
- Community herbal monograph on Avena sativa L., herba (EMEA/HMPC/202966/2007). https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-avena-sativa-l-herba_en.pdf
Methodology: Subpages evidence-led supplement pipeline v1